Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032327 | 1.00 | ALDH1A1 (0.51) | ALDH1A1ESR1ESR2SLC7A5OPRD1 | |
| SCHEMBL237566 | 0.87 | HTR2A (0.57) | ALDH1A1OPRD1TACR1PTPN1HTR2A | |
| SCHEMBL4633497 | 0.87 | HTR2A (0.57) | ALDH1A1OPRD1TACR1PTPN1HTR2A | |
| SCHEMBL5845125 | 0.87 | HTR2A (0.57) | ALDH1A1OPRD1TACR1PTPN1HTR2A | |
| Hydrochloric Acid SCHEMBL4633494 | 0.85 | HTR2A (0.55) | ALDH1A1OPRD1TACR1PTPN1HTR2A | |
| Hydrochloric Acid SCHEMBL2896538 | 0.85 | HTR2A (0.55) | ALDH1A1OPRD1TACR1PTPN1HTR2A | |
| Hydrochloric Acid SCHEMBL237565 | 0.85 | HTR2A (0.55) | ALDH1A1OPRD1TACR1PTPN1HTR2A | |
| Tyrosine Methyl Ester SCHEMBL313051 | 0.84 | ESR1 (0.63) | ALDH1A1ESR1ESR2SLC7A5LNPEP | |
| Tyrosine Methyl Ester SCHEMBL314923 | 0.84 | ESR1 (0.63) | ALDH1A1ESR1ESR2SLC7A5LNPEP | |
| Tyrosine Methyl Ester SCHEMBL1255129 | 0.84 | ESR1 (0.63) | ALDH1A1ESR1ESR2SLC7A5LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084943-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9593084-B2 | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | PARION SCIENCES, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140171447-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8569426-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8314215-B2 | Mild chemically cleavable linker system | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-11-20 | — | — | US | disclosed |
| CN-1336921-A | Fused ring heteroaryl and heterocyclic compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAN PHARM INC (US) | 2002-02-20 | — | — | CN | disclosed |
| EP-1161416-A1 | ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1147091-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1144364-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000051974-A1 | ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000043371-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000043354-A2 | MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | ALDH1A1 1425/4885ESR1 3971/4885ESR2 4586/4885 |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | ALDH1A1 1425/4885ESR1 3971/4885ESR2 4586/4885 |
| US-20140171447-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | ALDH1A1 1208/4885ESR1 4491/4885ESR2 2401/4885 |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | ALDH1A1 1208/4885ESR1 4491/4885ESR2 2401/4885 |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | ALDH1A1 755/4885ESR1 2941/4885ESR2 2654/4885 |
| US-20190084943-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | ALDH1A1 1208/4885ESR1 4491/4885ESR2 2401/4885 |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | ALDH1A1 755/4885ESR1 2941/4885ESR2 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.